2nd Annual Biosimilars Congress India 2017



The conference proved a great opportunity to meet with a diversity of people across the Biosimilars development pipeline and share ideas
Richard Easton
Technical Director
The conference provided a great platform to interact with the scientists, regulators and the manufacturers.
Shrikrishna Dadke
Vice President
Vimta Labs Ltd.
It was very informative and an excellent opportunity to understand challenges of biosimilars and regulatory expectation
Amarnath Jaiswal
Associate Vice President
Mylan Laboratories Limited
Congratulations to UBM India team for a well chalked and organized conference. Not only the sessions were well managed but also well sequenced, sessions were very informative and there were some valuable take home messages. The stalls were also interesting and has presented some deep insights in to the evolving technologies. Please try to include some speakers also from regulatory authorities next time, you can take my help in this, if required. But overall it was a pleasant experience to be part of 2nd Annual Biosimilars Congress 2017. Appreciate UBM and team for excellent event.
Vijay Nag
MJ Biotech Pvt. Ltd.
All presentations were informative. It enlightened me with the regulatory requirements for the biosimilars development, approach of US FDA and EMA, ICH guidelines for the characterization procedures and many technical, non-technical factors involved in development and post-developmental phases. Also, realized the development in the laboratory and manufacturing technologies.
Hrishikesh Joshi
Research Associate
Lupin Limited
The conference provides great insights into the Indian biosimilars industry and provides a good platform to network with other specialists and industry experts.
Anjan Selz
VP Head of Biosimilars EMEA
Lupin Limited
The event was well organized and a good combination of some interesting speakers and great networking opportunity amongst the companies attending. Also understood regulatory pathways and regulations for Bio-similar products.
Sunil Dolia
Sr. Manager
CPL Biologicals Pvt Limited
These kind of conferences are always useful for industry people. The expert had given good insight on various points not known to me. I met with my previous industry colleagues as well as met with new people to establish good network in biosimilars industry. overall the conference was very good.
Puneet Kumar Doshi
Regulatory Affairs
Serum Institute of India Pvt. Ltd.
Got information on the biosimilarity requirements for USFDA based on industry experience. Expectations for Analytical similarity requirements. Clarity on clinical trial requirements for below 40 amino acid biologicals. An Opportunity to network with the delegates
Shoba Shenoy
Senior Asst General Manager - Biologics
USV Private Ltd